Onconomics

Onconomics examines which chemotherapy works best and which is ineffective for cancer. It offers a detailed, easy-to-use summary of the effectiveness of a given chemotherapy agent. Its goal is to help the clinician select the most potent chemotherapy or combination of chemotherapies for a given situation, knowing that not all tumors behave the same way.

How does Onconomics work?

• The Onconomics test employs a dual approach, combining molecular and cellular methods to assess the effectiveness of various cancer therapies.
• The process involves the isolation of malignant cells through Fluorescence-Activated Cell Sorting (FACS) and negative selection. Then, it is followed by epigenetic analysis and viability assays which determine how well specific treatments can suppress cancer.
• The isolated cells are then expanded and divided into two groups: one set undergoes viability assays, while the other is subjected to transcriptomic microarrays, which assess the genetic and genomic profile.

Why choose the Onconomics test?

• Onconomics assesses the genome profile using a dual approach to evaluate specific cancer treatments and drugs.
• It offers an in-depth breakdown of the most suitable and successful treatment options for cancer.
• It serves as a guide to the treating physician as to the most effective chemotherapy vs a standard protocol which may not work as well. This is particularly important when second/third line treatments are used and found ineffective.
• It provides insights to target the cancer when it has mutated beyond current standard protocols;  eliminating the need for guesswork.